WINT•benzinga•
Windtree Therapeutics Received Advice From Intellectual Property And FDA Experts; Istaroxime May Receive New Chemical Entity Designation; Istaroxime Has USPTO Issued Method Of Patent Providing Protection Until 2039 And Pedning Method Of Using Patent Provi
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 6, 2025 by benzinga